


In the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A compound ~~having the~~ of formula (I)



wherein

X is N or CH;

Y is ~~NR₂CH₂~~, CH₂NR₂, NR₂CO, CONR₂, NR₂SO₂ or NR₂CONR₂

wherein R₂ is H or C₁-C₆ alkyl;

R₁ is H, C₁-C₆ alkyl or C₃-C₆ cycloalkyl;

R₃ is ~~C₁-C₆ alkyl, C₃-C₆ cycloalkyl or (CH₂)_n-aryl,~~

~~wherein aryl is phenyl or a heteroaromatic ring~~

~~containing one or two heteroatoms selected from N, O and~~

~~S and which (CH₂)_n-phenyl, wherein the phenyl may be~~

~~mono- or di-substituted with R₄ and/or R₅;~~

wherein R₄ is selected from

a) H,

b) C₁-C₆ alkyl,

c) C₃-C₆ cycloalkyl,

- d) halogen, . .
- e) CN, . .
- f) CF₃, .
- g) OH, .
- h) C₁-C₆ alkoxy, . .
- i) NR₆R₇, .
- j) OCF₃,
- k) SO₃CH₃, .
- l) SO₃CF₃, . .
- m) SO₂NR₆R₇, .
- n) phenyl, . .
- o) phenyl-C₁-C₆ alkyl,
- p) phenoxy, . .
- q) C₁-C₆ alkylphenyl,

r) an optionally substituted 5-, 6- or 7-membered heterocyclic ring containing one or two heteroatoms selected from N, O, S, SO and SO₂, wherein when the heterocyclic ring is 5- or 6-membered and contains one heteroatom, the heteroatom is not N and when the heterocyclic ring is 5- or 6-membered and contains two heteroatoms, the heteroatoms are not both N and wherein the substituent(s) is(are) selected from C₁-C₆ alkyl, C₃-C₆ cycloalkyl, phenyl-C₁-C₆ alkyl, (CH₂)_mOR₉ wherein m is 2-6 and R₉ is H,

C₁-C₆ alkyl, C₃-C₆ cycloalkyl or phenyl-C₁-C₆ alkyl,
and COR₈,

s) an optionally substituted 5- or 6-membered
heteroaromatic ring containing one or two
heteroatoms selected from N, O and S, wherein when
the heteroaromatic ring contains one heteroatom,
the heteroatom is not N and when the heteroaromatic
ring contains two heteroatoms, the heteratoms are
not both N and wherein the substituent(s) is(are)
selected from C₁-C₆ alkyl, C₃-C₆ cycloalkyl and
phenyl-C₁-C₆ alkyl, ~~or~~ and

t) COR₈;

wherein R₆ is H, C₁-C₆ alkyl or C₃-C₆ cycloalkyl; R₇
is H, C₁-C₆ alkyl or C₃-C₆ cycloalkyl; and R₈ is C₁-C₆
alkyl, C₃-C₆ cycloalkyl, CF₃, NR₆R₇, or phenyl, ~~a~~
~~heteroaromatic ring containing one or two~~
~~heteroatoms selected from N, O and S or a~~
~~heterocyclic ring containing one or two heteroatoms~~
~~selected from N, O, S, SO and SO₂;~~

R₅ is selected from H, OH, CF₃, OCF₃, halogen, C₁-C₆
alkyl ~~or~~ and C₁-C₆ alkoxy;

and n is 0-4;

~~as~~ wherein the compound is an (R)-enantiomers, an (S)-

enantiomers, or a racemate in the form of a free base or a pharmaceutically acceptable salt or solvate thereof.

2. (currently amended) A The compound according to claim 1 wherein Y is NR_2CO or CONR_2 .

3. (cancelled)

4. (currently amended) A The compound according to ~~any one of claims 1-3~~ claim 1, wherein R_1 is H or $\text{C}_1\text{-C}_6$ alkyl.

5. (cancelled)

6. (currently amended) A The compound according to ~~any one of claims 1-4~~ claim 1, wherein ~~R_3 is $(\text{CH}_2)_n$ -aryl which the~~ phenyl ring of substituent R_3 is substituted with R_4 , and R_4 ~~which~~ is an optionally substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from N, O and ~~S~~, Si or COR_8 .

7. (currently amended) A The compound according to ~~any one of claims 5 and 6~~ claim 6, wherein n is 0.

8. (currently amended) A The compound according to claim 6 wherein R₈ is NR₆R₇ ~~or a heterocyclic ring containing two heteroatoms selected from N and O.~~

9. (currently amended) A The compound according to ~~any one of claims 1-8~~ claim 1, wherein ~~X is N and~~ Y is NR₂CO.

10. (currently amended) A The compound according to claim 9 1 wherein ~~X is N,~~ Y is NR₂CO and R₄ is morpholino or COR₈.

11. (cancelled)

12. (currently amended) A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound of ~~any one of claims 1-11~~ claim 1 as an enantiomer or racemate, in the form of a free base or a pharmaceutically acceptable salt or solvate thereof optionally in association with diluents, excipients or inert carriers.

13. (currently amended) A ~~pharmaceutical formulation according to claim 12 for use in~~ method for the treatment of 5-hydroxytryptamine-mediated disorders, comprising administering to a patient in need of such treatment a

therapeutically effective amount of the pharmaceutical formulation of claim 12.

14-24. (cancelled)

25.. (currently amended) A method for the treatment of disorders in the central nervous system and/or urinary incontinence or vasospasm or for inhibiting tumor growth ~~control of tumors by~~ comprising administering to a mammal ~~including man~~ in need of such a treatment a therapeutically effective amount of a compound defined in ~~any of claims 1-11~~ claim 1.

26. (currently amended) A The method according to claim 25. ~~for the treatment of~~ wherein the disorders of the central nervous system are mood disorders, anxiety disorders, personality disorders, obesity, anorexia, bulimia, premenstrual syndrome, sexual disturbances, alcoholism, tobacco abuse, autism, attention deficit, hyperactivity disorder, migraine, memory disorders, pathological aggression, schizophrenia, endocrine disorders, stroke, dyskinesia, Parkinson's disease, thermoregulatory disorders, pain or hypertension.

27.. (currently amended) A method for the treatment of 5-hydroxytryptamine mediated disorders ~~by~~ comprising administering to a mammal ~~including man~~ in need of such a


treatment a therapeutically effective amount of a compound defined in ~~any of claims 1-11~~ claim 1.

28. (currently amended). A method ~~according to claim 27~~ wherein the compound according to ~~any one of claims 1-11~~ is ~~used as a~~ for the treatment of 5-hydroxytryptamine-mediated disorders in the central nervous system which require treatment with an h5-HT_{1B} antagonist, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound defined in claim 1.

29.. (currently amended). A process for the preparation of the compound of formula I according to claim 1 ~~by~~, comprising:

A(i)


acylation, in the case ~~when~~ wherein R₁ is C₁-C₆ alkyl or C₃-C₆ cycloalkyl, Y is NR₂CO, R₂ is hydrogen and X and R₃ are as defined ~~in general formula I~~ in claim 1, of a compound of formula A,



with an activated carboxylic acid $R_3\text{-COLg}_1$ wherein Lg_1 is a leaving group; or ~~by using~~ with a carboxylic acid $R_3\text{-COOH}$ ~~with~~ and an activating reagent;

A(ii)

acylation, in the case ~~when~~ wherein R_1 is hydrogen, Y is NR_2CO , R_2 is hydrogen, R_c is a protecting group and X and R_3 are as defined in ~~general formula I~~ in claim 1, of a compound of formula **B**




with an activated carboxylic acid $R_3\text{-COLg}_1$ wherein Lg_1 is a leaving group; or ~~by using~~ with a carboxylic acid $R_3\text{-COOH}$ ~~with~~ and an activating reagent, ~~followed by the removal of~~ and removing the protecting group R_c ;

A(iii)

debenzylation, in the case ~~when~~ wherein R_1 is $\text{C}_1\text{-C}_6$ alkyl or $\text{C}_3\text{-C}_6$ cycloalkyl, X and R_2 are as defined in ~~general formula I~~ above claim 1 and R_3 below is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, $(\text{CH}_2)_m\text{OH}$ wherein m is 2-6, or COR_8 , of a compound of formula **Ia**, followed by a) hydrogenation, b)


alkylation, c) alkylation and removal of a protecting group
or d) acylation;



B(i).

reacting ,in the case ~~when~~ wherein R_1 is C_1-C_6 alkyl or C_3-C_6
cycloalkyl, Y is $CONR_2$, and X, R_2 and R_3 are as defined in
~~general formula I above~~ claim 1, an activated carboxylic


acid of a compound of formula C;



with an aniline or an amine HNR_2R_3 ; or

B(ii)

reacting, in the case ~~when~~ wherein R_1 is hydrogen, Y is NR_2CO , R_c is a protecting group and X, R_2 and R_3 are as defined in ~~general formula I~~ above claim 1, an activated carboxylic acid of a compound of formula D




with an aniline or an amine HNR_2R_3 , ~~followed by removal of~~
and removing the protecting group R_c - R_c ; or

C


~~reaction~~ reacting, in the case ~~when~~ wherein R_1 is C_1 - C_6 alkyl

or C₃-C₆ cycloalkyl, Y is NR₂CONR₂, R₂ is hydrogen and X and R₃ are as defined in ~~general formula I above~~ claim 1, a compound of formula A,



with a suitable azide in the presence of a carboxylic acid, R₃COOH.

30. (currently amended) A compound ~~having~~ of the formula.



wherein

X=N ~~or~~ CH;

Z=NH₂ or COOH; and

R₁ is H, C₁-C₆ alkyl or C₃-C₆ cycloalkyl.